Compare Boston Scientific Corporation (BSX) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Workiva Inc — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while Workiva Inc trades at $53.58 (market cap $3.01B). The key difference: Boston Scientific Corporation is far larger — about 22× Workiva Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | WK | |
|---|---|---|
Market Cap | $66.37B | $3.01B |
Sector | Health | Technology |
52-Week High | $108.14 | $93.31 |
52-Week Low | $42.63 | $44.31 |
Enterprise Value | $75.94B | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Workiva (WK) trades at $54.54, up 4.54% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q1 2026 EPS of $0.77 exceeding expectations. Revenue growth remains solid at $884.57 million for 2025, projected to reach $926 million in 2026. Technical indicators show bullish moving averages while RSI levels suggest potential overbought conditions near-term.
Workiva presents a compelling growth story with 88.9% analyst buy ratings and a $71 consensus price target offering 30% upside. However, elevated valuation multiples (P/E 223.71, EV/EBITDA 71.73) and thin net margins (1.53%) warrant caution. Key risks include competitive pressures in compliance software and execution challenges in maintaining growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
